Aclaris market cap should be much greater than $300M: Cantor Fitzgerald

With two commercial drugs, Rhofade and Eskata, and up to six positive data readouts in 2019, Aclaris Therapeutics’ market capitalization should be much greater than $300M, Cantor Fitzgerald analyst Louise Chen tells investors in a research note titled “Don’t Make Me Tell You Until I’m Red In The Face.” The analyst believes Rhofade’s soft re-launch, which started on November 1, is gaining traction and that the drug’s “positive momentum is not getting the attention that it deserves.” Chen previously highlighted Aclaris as one of her top ideas heading into 2019 and she keeps an Overweight rating on the shares with a $50 price targe

https://thefly.com/landingPageNews.php?id=2842037